SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

Cepheid logo
4 weeks ago

Marketing Manager, Respiratory

Cepheid

Atlanta, GA (Remote)Full time$83K/yr – $110K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Cepheid logo

Marketing Manager, Respiratory

Cepheid

Atlanta, GA (Remote)

$83K/yr - $110K/yrIn-houseFull-timeMid level5+ years exp.
4 weeks ago
Cepheid logo
Cepheid

Marketing Manager, Respiratory

Atlanta, GA (Remote)

$83K/yr – $110K/yrMid Level5+ years expFull time

Posted 4 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own respiratory product marketing work across launch readiness, messaging, and demand gen; bridge sales, medical, and global teams to enable field efforts and content that moves adoption.

  • Own cross-functional go-to-market and launch readiness for respiratory products in a regulated setting.
  • Lead positioning, messaging, and demand-gen activities across digital and traditional channels with field enablement in mind.
  • Align with Sales, Medical Affairs, and Global Marketing to build training and customer-facing content that supports field teams.

Job Description

Own respiratory product marketing work across launch readiness, messaging, and demand gen; bridge sales, medical, and global teams to enable field efforts and content that moves adoption.

  • Responsibilities: Support execution of integrated U.S. marketing plans for assigned Respiratory products or programs, aligned to portfolio strategy and business objectives.
  • Responsibilities: Contribute to positioning, messaging, and customer engagement efforts for designated disease areas.
  • Responsibilities: Support regional product launches by coordinating assigned launch activities and cross‑functional inputs to ensure readiness and effective execution.
  • Responsibilities: Assist with demand generation initiatives across digital and traditional channels to drive awareness and adoption.
  • Responsibilities: Partner with Sales, Medical Affairs, and Global Marketing to develop and update field enablement tools, training materials, and customer‑facing content.
  • Requirements: Bachelor’s degree with 5+ years of relevant professional experience, or Master’s degree with 3+ years of relevant professional experience.
  • Requirements: Experience supporting product marketing, portfolio marketing, or go‑to‑market initiatives within regulated healthcare, diagnostics, medical devices, or life sciences.
  • Requirements: Experience working on cross‑functional projects in a matrixed organization.
  • Requirements: Exposure to integrated marketing campaigns across multiple channels (e.g., digital, field, events).
  • Requirements: Ability to analyze market, customer, or performance insights and translate them into recommendations for marketing execution.
  • Requirements: Travel Requirements – Ability to travel up to 40%, including occasional overnight travel, as business needs require.
  • Preferred: Exposure to respiratory disease areas, diagnostics, or molecular diagnostics through campaign support, product support, or launch participation.
  • Preferred: Participation in cross‑functional product launches or go‑to‑market initiatives within a regulated healthcare environment.
  • Preferred: Familiarity with sales enablement tools, CRM platforms, or marketing performance analytics used to support commercial teams.
  • Benefits: Cepheid, a Danaher operating company, offers a broad array of comprehensive, competitive benefit programs that add value to our lives. Whether it’s a health care program or paid time off, our programs contribute to life beyond the job. Check out our benefits at Danaher Benefits Info.
  • Benefits: At Cepheid we believe in designing a better, more sustainable workforce. We recognize the benefits of flexible, remote working arrangements for eligible roles and are committed to providing enriching careers, no matter the work arrangement. This position is eligible for a remote work arrangement in which you can work remotely from your home. Additional information about this remote work arrangement will be provided by your interview team. Explore the flexibility and challenge that working for Cepheid can provide.
  • Benefits: We offer comprehensive package of benefits including medical/dental/vision insurance and 401(k) to eligible employees.
Cepheid logo

Cepheid

3.4 Glassdoor

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com.Cepheid is proud to be a part of Danaher. Danaher’s science and technology leadership puts Cepheid’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.Together with Danaher’s other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Founded in 1996
Sunnyvale, California, USA
4.8K employees (148 in marketing)
www.cepheid.com
55% recommend to a friend
53% CEO approval

Traffic Signals

Monthly Visitors
77.8K
Monthly Google Ads Budget
$7.6K
Traffic Source Mix
Search
48%
Direct
39.9%
Referral
6.9%
Social
2.4%
Paid
2.8%

Headcount Trend

Current headcount: ~4.7K

Marketing Team

Marketing Team Size
126 (3% of company)
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$117.9M
Last Raise
$63.8M
Grant, 4 years ago

Funding History

  • Oct 2021
    Grant • $63.8M
  • Jul 2021
    Grant • $27M
  • Nov 2014
    Post IPO Equity • $3.3M

Recent News

Danaher subsidiary Cepheid implements layoffs
Nov 5, 2025 • The Business Journals
Cepheid announces WHO prequalification of the Xpert® MTB/XDR test
Nov 4, 2025 • European AIDS Treatment Group
Cepheid Announces World Health Organization Prequalification of the Xpert® MTB/XDR test
Oct 28, 2025 • PR Newswire
Danaher Q3 2025 Earnings Beat Estimates | Bioprocessing & Respiratory Testing Drive Growth - News and Statistics
Oct 28, 2025 • IndexBox
Danaher Corporation Q3 2025 Financial Results
Oct 21, 2025 • TradingView
Performance analysis of the GeneXpert respiratory panel prototype assay for the diagnosis of viral and bacterial upper respiratory tract infections
Sep 30, 2025 • ASM Journals
Radiometer, Leica Biosystems and Cepheid to come together at IBMS Congress 2025 on Stand 109
Sep 5, 2025 • News-Medical
Infectious Disease Diagnostics Market worth US$42.20 billion by 2030 with 9.7% CAGR | MarketsandMarkets™
Sep 5, 2025 • PR Newswire
Point of Care Molecular Diagnostics Market worth US$7.09 billion by 2030 with 10.5% CAGR | MarketsandMarkets™
Sep 3, 2025 • PR Newswire UK
Health Canada grants licence to Cepheid’s HCV test
Aug 20, 2025 • Medical Device Network
Cepheid Receives Health Canada Licence for Xpert® HCV VL Fingerstick
Aug 19, 2025 • PR Newswire Canada
Press Release Biocartis NV: Biocartis Welcomes Mike Kreitzinger as Senior Vice President of Global Business Development
Aug 18, 2025 • Biocartis NV
Danaher Discusses Diagnostics Biz at ADLM With Refocus on Partnerships in Key Disease Areas
Jul 31, 2025 • 360Dx
Danaher Discusses Diagnostics Biz at ADLM With Refocus on Partnerships in Key Disease Areas
Jul 31, 2025 • GenomeWeb
Best in Manufacturing Runner Up award at RFID Journal 2025
Jul 27, 2025 • linkedin.com
Ultrasensitive Molecular Amplification Market Research 2025-2035 | Demand Surges for Early Detection, Molecular Amplification Techniques Lead the Way
Jul 11, 2025 • GlobeNewswire News Room
Ashish Gupta joins Cepheid as GM
Jul 7, 2025 • Medical Buyer
Sexually Transmitted Diseases STD Testing Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams
Jul 2, 2025 • EIN Presswire
Cepheid Is Hiring: Manufacturing Supervisor in Bengaluru – Life Science Grads – Apply Now!
Jun 24, 2025 • BioTecNika
Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
Jun 20, 2025 • PR Newswire
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing market
Jun 16, 2025 • PharmiWeb
Point of Care (PoC) molecular diagnostics market
Jun 14, 2025 • PharmiWeb
Cepheid, a leader in molecular diagnostics, develops and distributes PCR test kits globally. To improve operations, Cepheid implemented RFID technology with Zebra and our partner, InThing Corp.
Jun 11, 2025 • linkedin.com
Visium RFID Program Launch
Jun 10, 2025 • linkedin.com
G2M Appoints Diagnostics Pioneer John Bishop, Former Cepheid CEO, to Its Advisory Board
Jun 9, 2025 • eHealth Magazine
Global Biomarkers Market Forecast: Key Growth Drivers, Trends, and Opportunities from 2025 to 2034
Jun 5, 2025 • EIN Presswire
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Jun 5, 2025 • BioSpace
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Jun 4, 2025 • PR Newswire Canada
Sepsis Diagnostics Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034
May 30, 2025 • EIN Presswire
Point of Care Diagnostics Market worth $68.5 billion by 2030 - Exclusive Report by The Research Insights
May 14, 2025 • PR Newswire UK
Influenza Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036
May 12, 2025 • Research and Markets
HIV Diagnostics Market Projected to Hit USD 1.80 Billion by 2032, Driven by Rising Global Testing Rates and Technological Advancements | SNS Insider
May 10, 2025 • SNS Insider pvt ltd
Holter ECG Market is expected to generate a revenue of USD 1.23 Billion by 2031, Globally, at 8.6% CAGR: Verified Market Research®
May 8, 2025 • Verified Market Research
Cepheid and Oxford Nanopore Technologies partner to advance automated sequencing-based solutions
May 1, 2025 • Drug Discovery News
Critical Care Diagnostics Market Projected to Reach USD 12.3 Billion, with a Robust 4.48% CAGR Till 2035
Apr 21, 2025 • EIN Presswire
RFID Journal Live!2025: Cepheid, Cummins, Kannegiesser Manufacturing IoT Implementation Finalists for RFID Journal Awards
Apr 15, 2025 • RFID Journal
Cepheid and Oxford Nanopore Technologies Partner To Advance Automated Sequencing-Based Solutions
Apr 14, 2025 • Technology Networks
Cepheid to lay off 167 people in California
Apr 14, 2025 • MedTech Dive
Oxford Nanopore inks infectious disease analysis pact with Cepheid
Apr 10, 2025 • Medical Device Network
Cepheid. (4/9/25). "Press Release: Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencing-based Solutions". Oxford & Sunnyvale, CA.
Apr 10, 2025 • mass-spec-capital.com
Other news to note for April 9, 2025
Apr 9, 2025 • BioWorld Financial Watch
Cepheid WARN Act Investigation
Mar 31, 2025 • Strauss Borrelli PLLC
Layoffs erase more than 600 Bay Area tech, biotech, hotel, retail jobs
Mar 28, 2025 • East Bay Times
Microbiology Testing Market Analysis, Trends, Opportunities, and Forecast 2025-2034
Mar 27, 2025 • EIN Presswire
2025 COVID-19 Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036
Mar 27, 2025 • Research and Markets
Respiratory Syncytial Virus RSV Diagnostics Market Report 2025: Size, Trends, And Growth Insights For Global Expansion
Mar 27, 2025 • EIN Presswire
Amebiasis Global Market Report 2025: Comprehensive Insights, Trends, And Forecasts
Mar 24, 2025 • EIN Presswire
Antimicrobial Resistance Surveillance Global Market Report 2025: Steady Growth, And Increased Awareness Propel Market
Mar 24, 2025 • EIN Presswire
Industry Voices—Time to rethink our approach to using one of modern medicine's miracles?
Mar 21, 2025 • Fierce Healthcare
Point-of-Care Diagnostics Market Size to Hit USD 91.47 Billion by 2032, Driven by Rising Demand for Rapid Testing Solutions – SNS Insider
Mar 21, 2025 • GlobeNewswire News Room
Global DNA Diagnostics Market Set to Surge, Reaching USD...
Mar 5, 2025 • PharmiWeb.com
Global Tuberculosis (TB) Diagnostics Market to Reach $3.80 Billion by 2032 | SNS Insider
Feb 25, 2025 • EIN Presswire
Next Generation Cancer Diagnostics Market Will Reach USD 42.0 Billion by 2034
Jan 28, 2025 • PharmiWeb.com
Blood Testing Instrument Market Anticipated to Reach USD 70.69 Billion, at a Notable 6.39% CAGR by 2032
Jan 23, 2025 • EIN Presswire
Antimicrobial Resistance Diagnostics Market Poised for Rapid Growth Amid Rising Global Health Concerns
Jan 17, 2025 • EIN Presswire
Sepsis Diagnostic Markets Global Market Forecasts 2024-2028: Instrumentation, Automation and Diagnostic Trends, Competitive Landscape, Recent Developments, Industry Overview
Nov 29, 2024 • GlobeNewswire News Room
Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts, Strategies, Trends, Forecasts with Executive Guides
Nov 28, 2024 • GlobeNewswire News Room
Health advocates press Cepheid for cheaper mpox tests
Nov 15, 2024 • Reuters
Dr. David H. Persing wins 2024 California Life Sciences Pantheon Award
Nov 12, 2024 • PR Newswire
Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs
Nov 6, 2024 • ASM Journals
Xpert® Mpox Receives Emergency Use Listing by World Health Organization
Nov 4, 2024 • PR Newswire
8 million people were infected with TB in 2023. WHO says that's the highest it has seen
Oct 29, 2024 • thepeninsulaqatar.com
Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance (AMR)
Sep 24, 2024 • PRNewswire
Cepheid Lays off 626 Employees in Manufacturing Consolidation Move
Aug 6, 2024 • GenomeWeb
Store closure, biotech layoffs jolt Bay Area job market with fresh cutbacks
Aug 5, 2024 • East Bay Times
Testmaker Cepheid to cut more than 600 jobs at Silicon Valley headquarters
Aug 5, 2024 • FierceBiotech
FDA clears its first fingerstick hepatitis C diagnostic, enabling test-to-treat approach
Jul 1, 2024 • FierceBiotech
FDA OKs 1st Point-of-Care Hepatitis C RNA Test
Jul 1, 2024 • Medical Product Outsourcing
Cepheid Receives FDA Authorization with CLIA Waiver for Xpert® HCV
Jul 1, 2024 • PR Newswire
FDA Approves Danaher Unit's Rapid Test for Hepatitis C
Jul 1, 2024 • MarketWatch
Danaher unit Cepheid wins approval of point-of-care hepatitis C test
Jun 28, 2024 • Seeking Alpha
FDA approves Cepheid's Xpert HCV test and GeneXpert Xpress System
Jun 28, 2024 • Yahoo Finance
Cepheid Receives FDA Authorization with CLIA Waiver for Xpert® HCV
Jun 28, 2024 • Yahoo Finance
Danaher unit Cepheid wins approval of point-of-care hepatitis C test
Jun 27, 2024 • SeekingAlpha
Cepheid Announces World Health Organization Prequalification of Xpert HIV-1 Qualitative Test
Apr 3, 2024 • PR Newswire
Cepheid Receives FDA Clearance for Xpert® Xpress GBS
Mar 11, 2024 • PR Newswire
Cepheid Receives FDA Clearance for Xpert® Xpress GBS
Mar 11, 2024 • Morningstar
Cepheid Receives CE Mark for Xpert® NPM1 Mutation
Jan 1, 1970 • PRNewswire UK
Cepheid Receives Health Canada Licence for Xpert® Xpress CoV-2 plus
Jan 1, 1970 • Canadian News Wire
Covid test developer Cepheid is cutting 625 more Silicon Valley employees
Jan 1, 1970 • Business Journals
Cepheid Receives CE Mark for Xpert® Xpress GBS
Jan 1, 1970 • PRNewswire UK
Cepheid Receives Emergency Use Authorization from FDA for Xpert® Mpox
Jan 1, 1970 • PRNewswire
Cepheid Announces Vitor Rocha as President
Jan 1, 1970 • PRNewswire
Cepheid Introduces Xpert GBS LB XC
Jan 1, 1970 • BioSpace
Danaher's Cepheid gets expanded FDA clearance for Xpert Xpress MVP
Jan 1, 1970 • SeekingAlpha
Cepheid, which made early Covid test, now cutting 1,000 Bay Area jobs
Jan 1, 1970 • Business Journals